US › Healthcare

Artelo Biosciences Inc (ARTL)

US · Healthcare · Biotechnology

$0.77+3.02%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-3.0M
Profit YoY
-24.7%
EPS
$-4.00

Key statistics

Market cap
$2.6M
Forward P/E
0.0
P/B
0.40
Book value
$7.62
EPS (TTM)
$-29.01
52-week high
$31.65
52-week low
$0.70
50-day MA
$1.19
200-day MA
$4.31
Beta
-0.07

Analyst view

Analysts rate Artelo Biosciences Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $18.00.

Shareholding

Insiders
2.47%
Institutions
7.72%

Largest institutional holders

FundStake
Jane Street Group LLC0.46%
Vanguard Capital Management, LLC0.36%
Vanguard Fiduciary Trust Co0.11%
Citigroup Inc0.11%
Tower Research Capital LLC0.10%
Clear Street Group Inc0.00%
Rothschild Wealth Partners0.00%
Advisor Group Holdings, Inc.0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Artelo Biosciences Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.